BS ISO 19617:2018

This is a preview of "BS ISO 19617:2018". Click here to purchase the full version from the ANSI store.



BSI Standards Publication

Traditional Chinese medicine — General requirements for the manufacturing process of natural products



National foreword

This British Standard is the UK implementation of ISO 19617:2018.

The UK participation in its preparation was entrusted to Technical Committee CH/100/1, Traditional Chinese Medicine.

A list of organizations represented on this committee can be obtained on request to its secretary.

This publication does not purport to include all the necessary provisions of a contract. Users are responsible for its correct application.

© The British Standards Institution 2018 Published by BSI Standards Limited 2018

ISBN 978 0 580 86660 9

ICS 11.120.10

Compliance with a British Standard cannot confer immunity from legal obligations.

This British Standard was published under the authority of the Standards Policy and Strategy Committee on 30 April 2018.

Amendments/corrigenda issued since publication

Date Text affected

INTERNATIONAL

This is a preview of "BS ISO 19617:2018". Click here to purchase the full version from the ANSI store.

First edition 2018-04-30

ISO

Traditional Chinese medicine — General requirements for the manufacturing process of natural products

Médecine traditionnelle chinoise — Exigences générales relatives au procédé de fabrication des produits naturels



Reference number ISO 19617:2018(E)



© ISO 2018, Published in Switzerland

All rights reserved. Unless otherwise specified, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office Ch. de Blandonnet 8 • CP 401 CH-1214 Vernier, Geneva, Switzerland Tel. +41 22 749 01 11 Fax +41 22 749 09 47 copyright@iso.org www.iso.org

Contents				Page
Fore	word			iv
Introduction				v
1	Scope Normative references			
2				
3	Tern	ns and de		
4	Assurance of manufacturing process			6
	4.1	Premises		
		4.1.1	General	
		4.1.2	Storage areas	б
		4.1.3	Production areas	
		4.1.4	Sanitation	
	4.2	Documentation		
		4.2.1	General	
		4.2.2	Crude drugs	
		4.2.3	Finished traditional Chinese medicinal products	
		4.2.4 4.2.5	Crude drug preparations Processing instructions	
	4.3	4.3 Personnel		
	т.5	4.3.1	General	
		4.3.2	Crude drug control manager	
		4.3.3	Training	
		4.3.4	Personnel hygiene	
	4.4	50		
	4.5	Deviation control		
	4.6	6 Self-inspections		
Anne	ex A (no	ormative]) Manufacturing control	
Annex B (normative) Quality control				
Bibliography				

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular, the different approval criteria needed for the different types of ISO documents shall be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see www.iso.org/patents).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation on the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT) see the following URL: www.iso.org/iso/foreword.html.

This document was prepared by Technical Committee ISO/TC 249, *Traditional Chinese medicine*.

Introduction

Natural products used in traditional Chinese medicine (TCM) are manufactured from materials of natural origin, the quality of which is varied according to geographical, climatic and seasonal conditions. For quality assurance of final products, quality evaluation on starting materials for natural products used in TCM is essential. On the other hand, it is also important to handle these natural materials appropriately and to control manufacturing processes for natural products used in TCM.

The management of manufacturing processes under good manufacturing practice (GMP) is indispensable to ensure quality of medicinal products. International GMP was issued by World Health Organization (WHO) in 1967, and a number of regional and international GMPs have subsequently been established. Recently, Pharmaceutical Inspection Convention (PIC)/Pharmaceutical Inspection Cooperation Scheme (PIC/S) has been widely applied around the world. At present, two-thirds of the member bodies of ISO/TC 249 are affiliated with PIC/S and some other countries are waiting for review of their applications.

These general GMPs were extensively applied to different fields and complimented with special supplements for herbal medicines in some countries and organizations. However, these herbal GMPs are focusing on European herbal medicines, but not covering those in the East Asian regions such as China, Japan and Korea where traditional medicines are used.

The current herbal GMPs of WHO, EU or PIC/S are mainly based on single herbal products, and the products consisting of more than one herbs were stipulated as special cases. However, multi-herbal products are more common than single-herbal products in the East Asian regions. In addition, raw materials in herbal GMPs of WHO, EU or PIC/S are only exclusive for plant origin, while traditional medicines in East Asia also include animal and mineral materials. In order to use correct materials, it is important to identify the starting materials not only by physical/chemical examinations but also by perceptive identification by well-trained experts. However, the requirement for experts on natural materials are not described in these international herbal GMPs. For a better safety and quality control of TCM products, conventional GMPs for the manufacturing of herbal medicines are in need of improving by this proposed standard.

Therefore, based on Chinese, Japanese and Korean herbal GMPs, and with reference to international GMPs, this document specifies general requirements for manufacturing processes that are particularly applied to natural products used in TCM. Implementation of this document with conventional GMPs for general pharmaceutical products would make it possible for manufacturers to ensure the safety and quality of natural products used in TCM, and at the same time prevent people in countries where such products are used from health hazards caused by poor quality products used in TCM for treatments of diseases as well as promoting health. This document will also allow non-PIC/S member countries to request quality assurance of the products to manufacturers and manufacturing countries with reference to this document. Finally, this document will make it possible to complement and/or amend WHO, EU and PIC/S herbal GMPs.

Traditional Chinese medicine — General requirements for the manufacturing process of natural products

1 Scope

This document specifies the general requirements for manufacturing processes to ensure the quality of finished products used in traditional Chinese medicine (TCM). This document covers premises, documentation, personnel, training, manufacturing control and quality control. This document applies to the manufacturing of natural products used in and as TCM.

This document does not conflict with general pharmaceutical good manufacturing practices (GMPs).

This document applies to all materials of natural origin: medicinal plants, medicinal animals, medicinal minerals, crude drugs or crude drug preparations.

2 Normative references

There are no normative references in this document.

3 Terms and definitions

For the purposes of this document, the following terms and definitions apply.

ISO and IEC maintain terminological databases for use in standardization at the following addresses:

- ISO Online browsing platform: available at http://www.iso.org/obp
- IEC Electropedia: available at http://www.electropedia.org/

NOTE Traditional Chinese medicines include various types of items. The same material can be classified in different categories (e.g. a powdered plant material can be both a crude herbal drug and a crude herbal drug preparation or, in a packed form, a traditional Chinese medicinal product).

3.1

active ingredient

crude drug(s) or the crude drug preparation(s) of a traditional Chinese medicine(s)

[SOURCE: WHO guidelines on good manufacturing practices (GMP) for herbal medicines, modified]

3.2

constituent of known therapeutic activity

substance or group of substances that is chemically defined and known to contribute to the therapeutic activity of a crude drug or of a preparation

[SOURCE: WHO guidelines on good manufacturing practices (GMP) for herbal medicines, modified]

3.3

marker substance

chemically defined constituent of a crude drug utilized for control purposes

Note 1 to entry: Marker substances contribute or not to the clinical efficacy. When they contribute to the clinical efficacy, however, evidence that they are solely responsible for the clinical efficacy can be available or not.

Note 2 to entry: Marker substances are generally employed when constituents of known therapeutic activity are not known or are not clearly identified, and are used to identify the crude drug or preparation or calculate their quantity in the finished product.